Focus: Adagene is a China-based biotechnology company specializing in antibody discovery and engineering for oncology indications. The company is publicly traded and focused on developing novel monoclonal antibodies and engineered therapeutics.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Adagene to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Adagene
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Adagene's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
+2 more
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types - The Manila Times
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types The Manila Times
Experimental Adagene drug lifts liver cancer response to 66.7% - Stock Titan
Experimental Adagene drug lifts liver cancer response to 66.7% Stock Titan
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board - GlobeNewswire
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board GlobeNewswire
Guggenheim raises Adagene stock price target on cancer drug data By Investing.com - Investing.com UK
Guggenheim raises Adagene stock price target on cancer drug data By Investing.com Investing.com UK
Adagene reveals Incyte deal, data update and public offering - The Pharma Letter
Adagene reveals Incyte deal, data update and public offering The Pharma Letter
Adagene (NASDAQ: ADAG) revenue jumps in 2025 as losses narrow and cash runway extends - Stock Titan
Adagene (NASDAQ: ADAG) revenue jumps in 2025 as losses narrow and cash runway extends Stock Titan
Showing 6 of 7 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications